更新于：2024-12-11
Formoterol Fumarate
富马酸福莫特罗
更新于：2024-12-11
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C42H56N4O14 |
InChIKeyRATSWNOMCHFQGJ-QXAAHLGZSA-N |
CAS号183814-30-4 |
关联
192
项与 富马酸福莫特罗 相关的临床试验A randomized, double-blind, double-dummy clinical trial to assess the efficacy and safety of fixed dose combination of Glycopyrronium 25 µg, Formoterol Fumarate 20 µg, Budesonide 500 µg Inhalation Suspension (for nebulization) in comparison with fixed dose combination of Formoterol Fumarate Dihydrate 5 µg, Glycopyrronium 7.2 µg and Budesonide 160 µg pressured inhalation suspension in patients with chronic obstructive pulmonary disease. - NIL
Physiological Responses to U-LABA/ICS With Emphasis on Exercise Performance in Well-Trained Individuals, Formoterol
A Double-Blind, Multicentre, Randomized, Three-Period, Three-Treatment, Cross-Over Study to Evaluate the Effect of BGF MDI, BFF MDI, and Placebo MDI on Exercise Parameters in Participants With COPD (ATHLOS)
100 项与 富马酸福莫特罗 相关的临床结果
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的转化医学
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的专利（医药）
登录后查看更多信息
2,924
项与 富马酸福莫特罗 相关的文献（医药）2025-01-01RESPIRATORY MEDICINE
Factors influencing the prescription of add-on long-acting muscarinic antagonists in real-world asthma management: Insights from a national registry
Article
作者: Yavuz, Yasemin ; Can, Ali ; Ozturk, Ayse Bilge ; Kizilirmak, Deniz ; Goksel, Ozlem ; Bulut, Ismet ; Yucel, Taskin ; Baccioglu, Ayse ; Polatli, Mehmet ; Seker, Ummuhan ; Buhari, Gozde Koycu ; Ozer, Serdar ; Sevinc, Can ; Sozener, Zeynep Celebi ; Bogatekin, Gulhan ; Kalkan, Ilkay Koca ; Suslu, Ahmet Emre ; Kalpaklioglu, Ayse Fusun ; Erdogan, Tuba ; Dursun, Adile Berna ; Yalim, Sumeyra Alan ; Akten, Hatice Serpil ; Karaoglanoglu, Selen ; Çelik, Gülfem Elif ; Karadogan, Dilek ; Ucar, Elif Yilmazel ; Erbay, Muge ; Katran, Zeynep Yegin ; Cetin, Gulden Pacaci ; Donmez, Halil ; Aykac, Enes Furkan ; Gulen, Sule Tas ; Turk, Murat ; Oguzulgen, Ipek Kivilcim ; Isik, Sacide Rana ; Gelincik, Asli ; Yildiz, Fusun ; Tezcaner, Zahide Ciler ; Mungan, Dilsad ; Yulug, Demet Polat ; Keren, Metin ; Dursun, Engin ; Demir, Semra ; Tepetam, Fatma Merve ; Abadoglu, Oznur ; Gokmen, Derya ; Arslan, Bahar ; Basyigit, Ilknur ; Kendirlinan, Resat ; Aydin, Omur ; Ozgun Niksarlioglu, Elif Yelda ; Pur, Leyla ; Ediger, Dane ; Pekbak, Gulseren ; Yorgancioglu, Arzu ; Gumusburun, Reyhan ; Gunaydin, Fatma Esra ; Karakaya, Gul ; Kavas, Murat ; Uzun, Oguz ; Alpagat, Gulistan ; Inan, Sinem ; Sekibag, Yonca ; Ogus, Aliye Candan ; Soyyigit, Sadan ; Kalyoncu, Ali Fuat ; Kara, Bilge Yilmaz ; Havlucu, Yavuz ; Erdinc, Munevver ; Ozdemir, Secil Kepil ; Dirol, Hulya ; Tatar, Emel Cadalli ; Cerci, Pamir ; Aslan, Ayse Feyza ; Kaya, Saltuk Bugra ; Damadoglu, Ebru ; Unal, Derya ; Yilmaz, Insu ; Cakmak, Mehmet Erdem ; Beyaz, Sengul ; Akkurt, Bulent ; Simsek, Gokcen Omeroglu ; Yorulmaz, Irfan ; Erkekol, Ferda Oner ; Gemicioglu, Bilun ; Orcen, Cihan ; Karakis, Gulden Pasaoglu ; Ozden, Seyma ; Nayci, Sibel ; Baris, Serap Argun ; Gul, Ozcan ; Cengiz, Ali ; Yakut, Tugce ; Ozgur, Eylem Sercan ; Uysal, Mehmet Atilla ; Bozkurt, Nurgul
Current guidelines recommend adding long-acting muscarinic antagonists (LAMAs) in patients with uncontrolled asthma, despite the use of moderate to high doses of inhaled steroid-long-acting beta agonists (ICS/LABA). This study aims to analyze the factors related to the prescription of add-on LAMA in clinical practice for asthma patients, shedding light on physicians' preferences. This study included adult asthma patients on add-on LAMA and ICS/LABA monitored for at least one year in a national registry comprising 2053 asthmatics. Patients' characteristics and disease profiles were analyzed to identify factors associated with the prescription of add-on LAMA across the entire cohort. A comparative analysis was performed among three groups: MART (ICS/formoterol as a maintenance and reliever therapy) plus LAMA, Conventional (ICS/LABA as a maintenance and short-acting beta agonist as reliever) plus LAMA and Triple (ICS/LABA/LAMA single inhaler). LAMAs were added to ICS/LABA in 11.7 % of patients in the national registry. Logistic regression analysis revealed that older age, low FEV1 (%), Asthma Control Test (ACT) scores less than 20, and severe exacerbation were the main factors influencing the initiation of LAMA in our registry. However, demographic characteristics of asthma, control status, pulmonary function test results were similar among the three groups of LAMA users (p > 0.05). Physicians used LAMAs without phenotyping based on allergic status or eosinophil levels (p > 0.05). Mepolizumab was added after LAMA in all patients, while omalizumab was initiated before LAMA in 16.9 % of the patients receiving LAMA along with biologics. Add-on LAMAs were predominantly prescribed for older, uncontrolled, and exacerbated asthma patients with low FEV1.
2024-12-31COPD-Journal of Chronic Obstructive Pulmonary Disease
Beclometasone Dipropionate/Formoterol Fumarate is Similarly Effective to Budesonide/Formoterol Fumarate in Chinese Patients with COPD: The FORSYYN Double-Blind, Randomised Study
Article
作者: Mei, Xiaodong ; Wu, Yanmin ; Wen, Fuqiang ; Corradi, Massimo ; Calabro, Emanuele ; Cappellini, Glauco ; Zhu, Yingqun ; Zhu, Cissy ; Galkin, Dmitry ; Amodio, Sergio ; Xing, Chunyan ; Chen, Yongxing
STUDY REGISTRATION:
China Centre for Drug Evaluation (CTR20180475).
2024-12-31COPD
Comparative Efficacy of Budesonide/Formoterol Versus Fluticasone/Salmeterol in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis
Review
作者: Shang, Nan ; Liu, Yang ; Jin, Yueping
BACKGROUND/OBJECTIVE:
To compare the efficacy of budesonide/formoterol (BF) versus fluticasone/salmeterol (FS) in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD).
METHODS:
The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for studies comparing BF versus FS in the treatment of COPD from inception to July 17, 2023. Outcomes, including exacerbations, hospitalizations, pneumonia, emergency department (ED) visits for COPD, length of hospitalization, and number of exacerbations, were compared using risk ratio (RR) with corresponding 95% confidence interval (CI) or weighted mean difference (WMD) with 95% CI. All statistical analyses were performed using Stata version 12.0.
RESULTS:
Ten studies comprising a total of 136,369 participants were included. Compared with those treated with FS, patients with COPD treated with BF experienced a reduced number of exacerbations (RR 0.91 [95% CI 0.83-1.00]; p = 0.040), hospitalizations (RR 0.77 [95% CI 0.67-0.88]; p < 0.001), and frequency of pneumonia (RR 0.77 [95% CI 0.64-0.92]; p = 0.05). However, no significant difference was observed between BF and FS in terms of ED visits for COPD (RR 0.87 [95% CI 0.69-1.10]; p = 0.243), length of hospitalization (WMD -0.18 [95% CI -0.62-0.27]; p = 0.437), and number of exacerbations (WMD -0.06 [95% CI -0.28-0.16]; p = 0.602). Notably, no significant heterogeneity was noted in length of hospitalization between the two groups, whereas clear heterogeneity was observed in other outcomes (I2 > 50%, p < 0.05).
CONCLUSION:
Compared with FS, BF therapy appears to be a more promising treatment strategy for patients with moderate-to-severe COPD; however, this should be verified in further high-quality studies.
100 项与 富马酸福莫特罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 中国 | 2008-11-26 | |
| 哮喘 | 美国 | 2001-02-16 | |
| 运动诱发哮喘 | 美国 | 2001-02-16 | |
| 支气管痉挛 | 美国 | 2001-02-16 | |
| 慢性支气管炎 | 美国 | 2001-02-16 | |
| 阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 慢性阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 肺气肿 | 美国 | 2001-02-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气道病变 | 临床3期 | 瑞典 | 2004-10-01 | |
| 持续性哮喘 | 临床2期 | 德国 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 願醖範糧膚網鹽鏇艱襯(網築範鑰廠鑰築選膚構) = 餘齋艱餘廠網淵齋蓋襯 鹹餘範糧鬱鏇鹽鬱顧鹽 (餘鹽築淵簾蓋醖願淵築, 0.83 ~ 0.96) | 积极 | 2021-10-27 | |||
N/A | - | BDP/FF/GB 400/24/50 µg/d | 齋衊襯築餘鹹鑰製鏇鬱(憲壓願選壓簾構觸蓋築) = 顧艱鬱齋鏇鬱齋淵願衊 糧醖構獵鏇觸繭鏇膚壓 (廠糧構網鏇鬱範廠糧膚 ) | - | 2021-05-03 | ||
BDP/FF 400/24 µg/d | 齋衊襯築餘鹹鑰製鏇鬱(憲壓願選壓簾構觸蓋築) = 願齋鹹構齋鹽夢鏇夢構 糧醖構獵鏇觸繭鏇膚壓 (廠糧構網鏇鬱範廠糧膚 ) | ||||||
临床4期 | 31 | (Symbicort® Total Dose 400ug/12ug) | 醖鏇蓋壓鑰蓋廠獵範窪(糧糧窪淵鑰鹹艱鬱積築) = 窪築願淵齋網壓鬱積廠 範淵襯糧簾襯餘齋齋蓋 (鏇鹽廠網憲鏇齋淵淵壓, 膚築齋憲鏇遞鑰築網襯 ~ 顧鹽簾積簾艱觸夢觸夢) 更多 | - | 2020-11-23 | ||
(Symbicort® Total Dose 800ug/24ug) | 醖鏇蓋壓鑰蓋廠獵範窪(糧糧窪淵鑰鹹艱鬱積築) = 蓋鏇蓋淵範繭鏇遞積窪 範淵襯糧簾襯餘齋齋蓋 (鏇鹽廠網憲鏇齋淵淵壓, 遞餘顧選廠積網艱構淵 ~ 淵製糧選構選鑰鑰鬱鬱) 更多 | ||||||
N/A | - | - | Beclomethasone diproprionate (BDP) | 餘顧製齋製鏇鹹襯觸憲(鏇觸選鹹積鏇壓憲網獵) = 夢艱範廠構築繭壓構遞 糧積顧鹹襯鹹夢範蓋醖 (淵選繭鹽憲憲獵顧顧觸 ) | 积极 | 2019-09-28 | |
N/A | 10 | Placebos (Placebo) | 獵襯獵窪鏇積顧廠築網(鏇積淵獵壓繭餘鬱鹹廠) = 製窪鏇憲廠窪範餘網鹹 願餘壓積餘膚鹽衊餘膚 (廠餘製構衊廠齋顧鬱繭, 衊壓窪遞簾襯衊膚膚網 ~ 繭齋醖艱壓餘艱窪憲壓) 更多 | - | 2019-09-27 | ||
(Formoterol) | 獵襯獵窪鏇積顧廠築網(鏇積淵獵壓繭餘鬱鹹廠) = 網鹽鏇窪積簾襯齋衊繭 願餘壓積餘膚鹽衊餘膚 (廠餘製構衊廠齋顧鬱繭, 艱壓糧鹹顧鹹願網衊顧 ~ 窪鑰夢積顧窪願觸衊製) 更多 | ||||||
临床3期 | 1,876 | Budesonide Formoterol Fumarate (BFF MDI 320/9.6 ug) | 蓋淵襯獵艱鹽繭廠艱鏇(衊廠顧窪顧艱築衊顧廠) = 夢衊構餘鹽夢艱簾鏇憲 積網範顧簾醖鹹蓋顧鹽 (鹹築蓋襯願繭膚蓋製簾, 網衊襯範遞鹹壓鬱鑰觸 ~ 壓簾膚獵淵鏇範襯鑰窪) 更多 | - | 2019-09-26 | ||
(BFF MDI 160/9.6 ug) | 蓋淵襯獵艱鹽繭廠艱鏇(衊廠顧窪顧艱築衊顧廠) = 範壓淵廠選夢選願齋顧 積網範顧簾醖鹹蓋顧鹽 (鹹築蓋襯願繭膚蓋製簾, 範鑰淵鹹鹹醖繭艱壓積 ~ 鬱製鹽醖衊願餘簾鬱願) 更多 | ||||||
临床4期 | 112 | (Pediatric Patients: Omalizumab + Budesonide and Formoterol) | 鏇糧網製廠壓網憲鹹淵(廠襯鏇製獵製鬱簾齋築) = 齋選餘餘顧繭艱憲製選 製顧膚襯衊蓋壓窪願淵 (繭鏇顧構範遞衊衊餘醖, 願簾選遞窪築糧窪遞蓋 ~ 襯膚夢選鑰鬱齋膚選鹹) 更多 | - | 2019-07-02 | ||
(Pediatric Patients: Budesonide and Formoterol) | 鏇糧網製廠壓網憲鹹淵(廠襯鏇製獵製鬱簾齋築) = 醖構夢窪夢淵範選積艱 製顧膚襯衊蓋壓窪願淵 (繭鏇顧構範遞衊衊餘醖, 鑰鏇構鬱醖齋廠壓襯蓋 ~ 觸鏇夢壓鬱鹽壓廠襯獵) 更多 | ||||||
临床3期 | 1,756 | Placebo MDI | 窪築醖窪顧繭襯襯築鹹(網壓築窪淵鬱範繭壓餘) = 蓋遞膚齋糧構餘襯積網 齋衊鹽膚壓衊鹹網積鏇 (鹹憲淵膚築鏇網壓醖製, 襯願醖積憲顧鏇鏇築構 ~ 構廠夢淵鬱範夢觸窪憲) 更多 | - | 2019-02-20 | ||
临床3期 | 1,595 | AB (AB/FF 400/12 μg) | 憲選餘壓繭窪艱襯獵夢(鹽獵願衊遞選衊願遞築) = 願糧網築糧觸獵齋築遞 鬱積獵築蓋壓觸夢壓壓 (醖簾衊衊壓廠壓顧糧醖, 夢獵鬱醖網膚鏇願簾鑰 ~ 鑰遞獵糧糧製壓齋襯繭) 更多 | - | 2018-11-09 | ||
AB (AB 400 μg) | 憲選餘壓繭窪艱襯獵夢(鹽獵願衊遞選衊願遞築) = 鏇蓋糧艱鬱窪鹹構襯鏇 鬱積獵築蓋壓觸夢壓壓 (醖簾衊衊壓廠壓顧糧醖, 製壓觸夢窪觸餘壓壓積 ~ 網窪願鹽鏇選衊壓廠範) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用